INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update

INmune Bio, Inc. (NASDAQ:INMB) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 5,510,000 shares, a growth of 9.5% from the January 15th total of 5,030,000 shares. Based on an average daily trading volume, of 330,500 shares, the days-to-cover ratio is currently 16.7 days.

Wall Street Analyst Weigh In

INMB has been the subject of several analyst reports. Scotiabank raised their target price on shares of INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Tuesday, February 11th. RODMAN&RENSHAW raised shares of INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th. Maxim Group raised their target price on shares of INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday. Alliance Global Partners initiated coverage on shares of INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 target price for the company. Finally, Rodman & Renshaw initiated coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They issued a “buy” rating and a $23.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, INmune Bio has an average rating of “Buy” and an average price target of $22.80.

INmune Bio Price Performance

INmune Bio stock traded down $0.12 during mid-day trading on Friday, hitting $9.18. 311,175 shares of the company’s stock traded hands, compared to its average volume of 514,959. The firm has a 50 day simple moving average of $6.61 and a two-hundred day simple moving average of $6.12. INmune Bio has a fifty-two week low of $4.32 and a fifty-two week high of $14.49. The stock has a market cap of $203.54 million, a price-to-earnings ratio of -4.21 and a beta of 1.87.

Institutional Investors Weigh In On INmune Bio

Several hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN lifted its holdings in shares of INmune Bio by 51.0% during the fourth quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock worth $30,000 after buying an additional 2,155 shares in the last quarter. Beacon Pointe Advisors LLC acquired a new stake in shares of INmune Bio during the fourth quarter worth $48,000. JPMorgan Chase & Co. lifted its holdings in shares of INmune Bio by 93.0% during the fourth quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock worth $53,000 after buying an additional 5,461 shares in the last quarter. Mariner LLC acquired a new stake in shares of INmune Bio during the fourth quarter worth $65,000. Finally, Financial Advocates Investment Management lifted its holdings in shares of INmune Bio by 14.8% during the fourth quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock worth $72,000 after buying an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.